A method for capturing CO.sub.2 comprising dissolving at least one pure amino acid (AA) in water without the use of a catalyst for establishing protonation of an amino group of the amino acid, adding at least one base solution to the amino acid and water solution to deprotonate the protonated amino group of the amino acid and forming an amino acid-XOH—H.sub.2O wherein X is sodium or potassium, and subjecting CO.sub.2 to the amino acid-XOH—H.sub.2O to form new nanomaterials is provided. A regenerable nanofiber is disclosed comprising a NaHCO.sub.3 nanofiber, a KHCO.sub.3 nanofiber, or an amino acid nanofiber made from subjecting a CO.sub.2 gas to an amino acid aqueous solvent. Preferably, the amino acid aqueous solvent is one or more of a Gly-NaOH—H.sub.2O, an Ala-NaOH—H.sub.2O, a Phe-NaOH—H.sub.2O, a Gly-KOH—H.sub.2O, an Ala-KOH—H.sub.2O, and a Phe-KOH—H.sub.2O.

A method for capturing CO.sub.2 comprising dissolving at least one pure amino acid (AA) in water without the use of a catalyst for establishing protonation of an amino group of the amino acid, adding at least one base solution to the amino acid and water solution to deprotonate the protonated amino group of the amino acid and forming an amino acid-XOH—H.sub.2O wherein X is sodium or potassium, and subjecting CO.sub.2 to the amino acid-XOH—H.sub.2O to form new nanomaterials is provided. A regenerable nanofiber is disclosed comprising a NaHCO.sub.3 nanofiber, a KHCO.sub.3 nanofiber, or an amino acid nanofiber made from subjecting a CO.sub.2 gas to an amino acid aqueous solvent. Preferably, the amino acid aqueous solvent is one or more of a Gly-NaOH—H.sub.2O, an Ala-NaOH—H.sub.2O, a Phe-NaOH—H.sub.2O, a Gly-KOH—H.sub.2O, an Ala-KOH—H.sub.2O, and a Phe-KOH—H.sub.2O.

An organic amine salt compounds of general formula A.sup.n−[B.sup.m+].sub.p (I) is disclosed, wherein A.sup.n− is a CO.sub.2-donating anion with a valence of −n, wherein n=1, 2 or 3; each B.sup.m+ comprises: ammonium ion, hydrazinium ion and/or organic amine B cation; wherein $m=1\text{-}10;0<p\le \frac{n}{m};$
and wherein A.sup.n− is one or more selected from a group consisting of following anions: (a) carbamate orcarbazate; (b) carbonate; (c) formate; (d) bicarbonate; (e) organic monocarbonate; (f) organic poly-carbamate; (g) orthoformate; or (h) organic poly-carbonate. The compound of general formula (I) has at least one of hydroxyalkyl group linked to N atom, i.e., has alkanolamine residue. They can be used as polyurethane foaming agent, and most of them can be used as polystyrene foaming agent or polyvinyl choride foaming agent.

An organic amine salt compounds of general formula A.sup.n−[B.sup.m+].sub.p (I) is disclosed, wherein A.sup.n− is a CO.sub.2-donating anion with a valence of −n, wherein n=1, 2 or 3; each B.sup.m+ comprises: ammonium ion, hydrazinium ion and/or organic amine B cation; wherein $m=1\text{-}10;0<p\le \frac{n}{m};$
and wherein A.sup.n− is one or more selected from a group consisting of following anions: (a) carbamate orcarbazate; (b) carbonate; (c) formate; (d) bicarbonate; (e) organic monocarbonate; (f) organic poly-carbamate; (g) orthoformate; or (h) organic poly-carbonate. The compound of general formula (I) has at least one of hydroxyalkyl group linked to N atom, i.e., has alkanolamine residue. They can be used as polyurethane foaming agent, and most of them can be used as polystyrene foaming agent or polyvinyl choride foaming agent.

The present invention relates to a serine derivative compound having improved blood-brain barrier (BBB) permeability and the use thereof, and more particularly, to a novel serine derivative compound having improved blood-brain barrier permeability compared to L-serine, and a pharmaceutical composition for preventing, treating or alleviating nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, the pharmaceutical composition containing the compound as an active ingredient. The compound of Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient for the pharmaceutical composition for preventing or treating central nervous system diseases according to the present invention exhibits significantly improved blood-brain barrier permeability, activates neuronal cell proliferation, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, the food industry and the livestock industry.

The present invention relates to a serine derivative compound having improved blood-brain barrier (BBB) permeability and the use thereof, and more particularly, to a novel serine derivative compound having improved blood-brain barrier permeability compared to L-serine, and a pharmaceutical composition for preventing, treating or alleviating nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, the pharmaceutical composition containing the compound as an active ingredient. The compound of Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient for the pharmaceutical composition for preventing or treating central nervous system diseases according to the present invention exhibits significantly improved blood-brain barrier permeability, activates neuronal cell proliferation, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, the food industry and the livestock industry.

The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them:

##STR00001##

wherein meanings of the substituents are indicated in the description.

Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) ##STR00001##
wherein R.sub.1 and R.sub.2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and A.sup.n+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that A.sup.n+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H.sub.2NR.sub.1R.sub.2.sup.+−OC═ONR.sub.1R.sub.2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.